Researchers have developed an algorithm that can take either single-cell mass cytometry data or RNA sequencing data, align it, and extract a common denominator for comparing cancer data among patients. The algorithm, called tuMap, was detailed in a study published on October 7 in Cell Systems.  

French biotechnology firm GenSight Biologics is highlighting its lenadogene neparvovec (Lumevoq) and GS030 gene therapies at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.  

Forge Biologics will deliver a presentation about its adeno-associated virus gene therapy at the upcoming Cell & Gene Meeting on the Mesa in Carlsbad, CA.  

Artisan Bio plans to highlight its CRISPR-engineered cell therapy platform at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.  

French biotechnology firm GenSight Biologics is highlighting its lenadogene neparvovec (Lumevoq) and GS030 gene therapies at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.  

MilliporeSigma has opened a second contract development manufacturing facility in California to focus on viral vector technologies for cell and gene therapy.  

Biotechnology firm Applied Genetic Technologies (AGTC) President and CEO Sue Washer will present at the Cell & Gene Meeting on the Mesa in Carlsbad, CA, on October 13 at 11:15 a.m. PT.  

Researchers have developed an algorithm that can take either single-cell mass cytometry data or RNA sequencing data, align it, and extract a common denominator for comparing cancer data among patients. The algorithm, called tuMap, was detailed in a study published on October 7 in Cell Systems.  

GeneCentric Therapeutics has formed a strategic partnership with Labcorp to develop and commercialize RNA-based gene signatures for oncology diagnostics.  

Ensoma has named Emile Nuwaysir, PhD, as its new president and CEO. Nuwaysir is currently chair of the Alliance for Regenerative Medicine and vice chair of Invenra, an antibody platform company he co-founded in 2011.  

Mission Bio has unveiled its Tapestri Cell & Gene Therapy Solutions, a new addition to its Tapesti platform that can provide analytical characterization of genotype with phenotype simultaneously.  

Faraz Ali, CEO of biotechnology firm Tenaya Therapeutics, will present on October 13 at 3:15 p.m. PT as part of a panel discussion at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.  

Aceto has acquired A&C Bio Buffer, a good manufacturing practices manufacturer of custom buffer and chemical blend products used in biopharmaceutical drug manufacturing.